Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

REVIVA PHARMACEUTICALS HOLDINGS, INC.

(RVPH)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

REVIVA PHARMACEUTICALS HOLDINGS, INC. : Results of Operations and Financial Condition (form 8-K)

05/10/2021 | 09:33am EDT

Item 2.02 Results of Operations and Financial Condition.

In connection with a proposed public offering of shares of common stock of Reviva Pharmaceuticals Holdings, Inc. (the "Company"), the Company is disclosing selected preliminary operating results for the quarter ended March 31, 2021 and certain preliminary financial condition information as of March 31, 2021, as set forth below:

• Net operating loss for the three months ended March 31, 2021 is expected to be approximately $1.9 million.

• A gain on remeasurement of warrant liability is expected to be recorded for approximately $923,000, which will be included as other income, a non-operating financial statement line item on the Company's statement of operations for the three months ended March 31, 2021.

• Cash as of March 31, 2021 was approximately $5.6 million. If the Company does not obtain additional financing, either through the completion of the proposed public offering or via other financing alternatives, or the Company does not prudently manage its expenses, its financial condition, cash flows and results of operations could be materially and adversely affected.

The above information is preliminary financial information for the first quarter of 2021 and subject to completion. The unaudited, estimated results for the first quarter of 2021 are preliminary and were prepared by the Company's management, based upon its estimates, a number of assumptions and currently available information, and is subject to revision based upon, among other things, quarter-end closing procedures and/or adjustments, the completion of the Company's interim consolidated financial statements and other operational procedures. This preliminary financial information is the responsibility of management and has been prepared in good faith on a consistent basis with prior periods. However, the Company has not completed its financial closing procedures for the quarter ended March 31, 2021, and its actual results could be materially different from the preliminary financial information, which preliminary information should not be regarded as a representation by the Company or its management as to the Company's actual results for quarter ended March 31, 2021. In addition, Armanino LLP, the Company's independent registered public accounting firm, has not audited, reviewed, compiled, or performed any procedures with respect to this preliminary financial information and does not express an opinion or any other form of assurance with respect to this preliminary financial information. During the course of the preparation of the financial statements and related notes as of and for the quarter ended March 31, 2021, the Company may identify items that would require the Company to make material adjustments to this preliminary financial information. As a result, prospective investors should exercise caution in relying on this information and should not draw any inferences from this information. This preliminary financial information should not be viewed as a substitute for full financial statements prepared in accordance with United States generally accepted accounting principles and reviewed by the Company's auditors.

The Company's financial statements and related notes as of and for the quarter ended March 31, 2021 may not be filed with the SEC until after the proposed public offering is completed. The Company expects to file its Quarterly Report on Form 10-Q including its financial statements for the quarter ended March 31, 2021 on or about May 17, 2021.

The information furnished under this Item 2.02 shall not be considered "filed" under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be incorporated by reference into any future filing under the Securities Act of 1933, as amended, or under the Exchange Act, unless the Company expressly sets forth in such future filing that such information is to be considered "filed" or incorporated by reference therein.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about REVIVA PHARMACEUTICALS HOLDINGS, INC.
09/15Reviva Pharmaceuticals to Present at the Upcoming Benzinga Healthcare Small C..
GL
09/02REVIVA PHARMACEUTICALS : to Present at the H.C. Wainwright 23rd Annual Global In..
AQ
08/16REVIVA PHARMACEUTICALS : Reports Second Quarter 2021 Financial Results and Recen..
PU
08/16REVIVA PHARMACEUTICALS HOLDINGS, INC : Results of Operations and Financial Condi..
AQ
08/16REVIVA PHARMACEUTICALS : Reports Second Quarter 2021 Financial Results and Recen..
AQ
08/16Reviva Pharmaceuticals Holdings, Inc. Announces Earnings Results for the Seco..
CI
08/16REVIVA PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDI..
AQ
08/16Reviva Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Second..
CI
07/26REVIVA PHARMACEUTICALS : Maxim Group Initiates Reviva Pharmaceuticals at Buy Rat..
MT
06/28Reviva Added to Russell Microcap® Index
GL
More news
Analyst Recommendations on REVIVA PHARMACEUTICALS HOLDINGS, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -11,4 M - -
Net Debt 2021 - - -
P/E ratio 2021 -5,29x
Yield 2021 -
Capitalization 59,8 M 59,8 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 -
Nbr of Employees 5
Free-Float 59,7%
Chart REVIVA PHARMACEUTICALS HOLDINGS, INC.
Duration : Period :
Reviva Pharmaceuticals Holdings, Inc. Technical Analysis Chart | RVPH | US76152G1004 | MarketScreener
Technical analysis trends REVIVA PHARMACEUTICALS HOLDINGS, INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 4,47 $
Average target price 14,50 $
Spread / Average Target 224%
EPS Revisions
Managers and Directors
Laxminarayan Bhat President, Chief Executive Officer & Director
Narayan Prabhu Chief Financial Officer
Parag Phoolchand Saxena Chairman
Marcus Cantillon Chief Medical Officer
Richard A. Margolin Independent Director
Sector and Competitors
1st jan.Capi. (M$)
REVIVA PHARMACEUTICALS HOLDINGS, INC.-48.89%60
MODERNA, INC.311.65%173 588
LONZA GROUP AG32.35%60 074
IQVIA HOLDINGS INC.43.07%49 116
CELLTRION, INC.-23.26%31 904
SEAGEN INC.-10.81%28 420